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The effect of thyroid hormone on bone
metabolism and osteoporosis
Annie W. C. Kung
Abstract
Thyrotoxicosis has long been known to accelerate bone turnover and thus increase the risk for
developing osteoporosis, especially in peri- and postmenopausal women. Increasingly sophisti-
cated tests of thyroid function have indicated that minor degrees of hyperthyroidism are common
in patients taking thyroxine (T4) therapy. Recent reports have suggested that women taking
TSH-suppressive doses of T4 have reduced bone density. An overview of the effects of thyroid
hormone on bone metabolism is presented. The use of sensitive TSH assays can now permit
extremely accurate titration of the T4 dosage and should obviate the potential side effects of
excessive therapy that results in iatrogenic subclinical thyrotoxicosis.
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Introduction
Thyroid hormone is essential for normal bone matu-
ration in utero and in early life, as hypothyroid infants
show features of delayed ossification at epiphyseal
centres and children with hypothyroidism have
stunted growth and short stature.1 In contrast,
hyperthyroidism in childhood may accelerate linear
growth and bone maturation.2 In adults, recent evi-
dence shows that an excess of thyroid hormones affects
the remodelling system in cortical and trabecular bone
and may contribute to the development of
osteoporosis.
Cellular mechanism of thyroid hormone
Thyroid hormone increases calcium release from fe-
tal rat long bone cultures, and increases osteoclast
number and activity.3 In vivo, thyroid hormone also
\stimulates osteoblast activity.4, 5 T3 receptor has been
demonstrated in osteoblasts6 but not osteoclasts, sug-
gesting that increased osteoclast activity in bone
cultures with T3 treatment is secondary to osteoblast
activation.
Bone remodelling normally consists of cyclical
erosion and repair of resorptive cavities on bone sur-
face. The bone balance depends on the frequency
with which the new cycles are initiated by the event
of activation and the focal balance in each remodel-
ling site. The latter depends on the depth of the
resorption cavity and the thickness of new bone de-
posited within the cavity by the osteoblasts, or wall
thickness of the bone structure units. In hyper-
thyroidism the activation frequency is increased and
the mineralization time is shortened, resulting in un-
coupled bone resorption and decreased mean wall
thickness.7 Conversely, in hypothyroidism, activation
frequencies are reduced and the phrase of the remod-
elling cycle are markedly prolonged. The final
resorption depth is reduced whereas the mean wall
thickness is increased. The final result is little change
in the bone mass.
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Thyroid hormone and calcium metabolism
Serum calcium level tends to be high in hyperthy-
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roidism due to accelerated bone resorption. In a care-
fully controlled study, the prevalence of hypercalcemia
is around 8.5%.8 The degree of hypercalcemia is usu-
ally mild and is just an incidental finding. Increases
in serum calcium together with accelerated bone
turnover suppress 1,25(OH)2D3 synthesis9 and inhibit
parathyroid hormone release.10 These together with
an increased intestinal motility reduce intestinal cal-
cium absorption. Urinary calcium excretion is also
increased in hyperthyroidism. These abnormalities
usually revert to normal after treatment.
Bone markers in thyroid diseases
Increased serum or urine markers for bone turnover
are observed in hyperthyroidism and the converse
was seen in hypothyroidism. These markers include
serum alkaline phosphatase (an enzyme produced by
osteoblasts),11 serum osteocalcin (bone GLA protein,
a non-collagenous bone matrix protein synthesized
by osteoblast),12 urinary hydroxyproline13 and 3-
hydroxy-pyridinium derivatives (pyridinoline and
deoxypyridinoline collagen fibres released during
bone resorption)14. Increased urinary hydroxyproline15
and pyridinoline14 excretion have been reported in
patients with low serum TSH levels or on exogenous
T4 therapy without clinical signs and symptoms of
thyrotoxicosis.
Bone mass in thyrotoxicosis
Although changes in the skeleton of patients with
thyrotoxicosis were described as early as 1891, clini-
cal manifestations of bone lesions are uncommon.
The incidence of bone changes ranged from 3.5 to
50%,16 depending on the methodology and criteria
used to define demineralization. Using noninvasive
bone densitometric techniques, a number of studies
have demonstrated that endogenous thyrotoxicosis
due to either Graves' disease, toxic adenoma or
multinodular goitre is associated with loss of bone
mineral content (BMC) at multiple sites in the skeleton.
Thyrotoxicosis reduces the amount of both cortical
and trabecular bone, with bone loss occurring more
severe in peri- and postmenopausal women.16-18
However, young patients also have lower BMC when
compared with age- and sex-matched controls.19 Some
workers observed a significant correlation between
the degree of bone turnover with thyroid activity5
while others found no relation to the duration or the
degree of hyperthyroidism.19
Is thyrotoxic bone loss permanent or can it be re-
stored? Krolner et al20 found a reduction of BMC of
12.6% in thyrotoxicosis and a gain of 3.6% after one
year of treatment, and Bayley et al.21 reported a 12.9%
increase in total body calcium two years after treat-
ment of thyrotoxicosis. The restoration of bone mass
after successful treatment of hyperthyroidism is be-
lieved to be related to the prolonged effect of increased
bone formation associated with thyrotoxicosis.
Whether this degree of bone loss is clinically significant
is subject to dispute. Solomon and Burman22 recently
reported that the prevalence of all types of fractures
in subjects who have a previous history of thyroid
disease is not different from controls but patients
with a history of thyrotoxicosis have their first fracture
occurring at a younger age. Further longitudinal
studies are required to examine the effect or potential
risks of endogenous thyrotoxicosis on bone.
Bone mass and thyroxine therapy
With the availability of sensitive TSH assays, it is
now possible to determine whether the replacement
dose of T4 in the treatment of primary hypothyroidism
is excessive. Long term T4 therapy that aims at main-
taining euthyroidism with TSH levels in the normal
range has been showed to be associated with a small
decrement in vertebral and femoral bone density in
both pre- and postmenopausal women.23 Bone loss in
the hip and wrists was also observed in
premenopausal women on physiologic dosage of T4
replacement therapy, with the degree of bone loss at
the femoral neck region negatively correlated with
the serum thyroid hormone levels.24 As for patients
with non-toxic goitres and thyroid cancer who re-
quire life-long T4 suppressive therapy to suppress
TSH secretion, bone loss is observed in both pre- and
postmenopausal women. Table 1 summarizes the
studies performed on patients taking suppressive
doses of T4. Most of the studies reported evidence of
bone loss, with estrogen deprivation in the
postmenopausal women having a greater degree of
loss. However, not all workers agree that T4 treat-
ment would result in bone loss. A few studies showed
that exogenous T4 therapy did not have a significant
effect on bone mineral density and hence on risk of
osteoporosis.31-33 The reasons for the difference in ob-
servation are unclear. Whether this could be related
to the dietary calcium and vitamin D intake, the
amount of sunlight exposure and physical activity
remains to be elucidated. It has to be noted that dietary
calcium intake is generally much lower in Asians
than Caucasians and this may contribute an additional
risk for developing bone loss during T4 therapy.
The question of adjunctive therapy to prevent rapid
bone loss during T4 therapy arises, especially in
postmenopausal women and older individuals who
present with symptomatic or severe bone loss. This
question is difficult to address in view of lack of
consensus regarding the pathopharmacology of T4
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Table 1. Bone mineral density in patients on T4 suppression therapy
Author
Rose et al., 25
Paul et al., 26
Diamond et al., 27
Lehmke et al., 28
Taelman et al., 29
Kung et al., 30
Franklyn et al., 31
Ribot et al., 32
Toh & Brown, 33
Mean
dose of
L-T4
(mg/day)
0.171
0.175
816a
337a
0.201
0.089
0.100
0.179
0.191
0.154
0.131
Mean
serum
T4
(ug/dl)
13.5
10.4
156b
165b
195b
2.4°
2.5C
177b
24.5d
17.3d
7.9
Mean
duration of
treatment
(years)
>5
>5
10.7
5.9
5.0
5.8
>10
12
7.9
>2
3.0
Method
of
detection*
DPA
DPA
DPA
DPA
CT + SPA
SPA
SPA
DEXA
DEXA
DPA
SPA
Menopausal
status
Premenopausal
Premenopausal
Premenopausal
Postmenopausal
Premenopausal
Premenopausal
Postmenopausal
Postmenopausal
Postmenopausal
Pre- and
Postmenopausal
Pre-and
Postmenopausal
Male
Region of
Study
Forearm
Femoral neck
Trochanter
Lumbar spine
Femoral neck
Forearm
Lumbar spine
Femoral neck
Forearm
Lumbar spine
Calcanus
Radius mildshaft
Lumbar Spine
Radius
Radius
Calcanus
Radius midshaft
Lumbar spine
Femur
Ward's triangle
Lumbar spine
Femur
Ward's triangle
Lumbar spine
Lumbar spine
Distal radius
Reduction
in
BMD
9%
12.8%
10%
NS
11%
NS
NS
23%
11%
16%
NS
NS
NS
5%
20%
22%
14.8%
NS
14.3%
16.7%
14.2%
NS
NS
NS
NS
NS
* DPA, dual-photon absortiometry;
absorptiometry
a Cumulative dose (mg)
b Total T4 (nmol/l)
c Total T3 (nmol/l)
d Free T4 (pmol/l)
CT, computed tomography; SPA, single-photon absortiometry; DEXA, dual-energy x-ray
induced bone loss. For patients who require replace-
ment therapy for treating hypothyroidism, sensitive
TSH assays allow accurate titration of the T4 dosage
to avoid over-treatment.34 This will also help to avoid
the other undesirable and deleterious side effects of
increased tissue catabolism and increased cardiac load.
Obviously, it must also be remembered that there
may be important consequences of minor degrees of
hypothyroidism arising from undertreatment with T4
with respect to the influences on circulating lipids
and hence ischaemic heart disease risk. For those with
non-toxic goitre and thyroid cancer who require sup-
pressive therapy, controversy still persists regarding
the dosage of T4 to achieve the serum thyroid hormone
and the degree of TSH suppression. As for subjects
with endogenous thyrotoxicosis, adequate treatment
to avoid prolonged period of hyperthyroidism and
multiple relapses is mandatory. So far, therapeutic
intervention for T4 induced bone loss is still debatable.
Further studies of antiresorptive therapy are required
before any recommendation is to be given related to
patients on long term T4 therapy.
Conclusion
Thyroid hormone increases bone turnover with bone
resorption exceeding formation. Physicians treating
perimenopausal and postmenopausal women who
are at increased risk of osteoporosis should be aware
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of the additional risk of bone loss associated with
hyperthyroidism or thyroxine therapy. Careful moni-
toring of thyroid status is necessary in patients
receiving thyroxine replacement therapy to avoid
over-treatment. Biochemical monitoring of bone
markers in conjunction with densitometric studies
may be necessary in individuals who have an in-
creased risk of fracture.
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